DHMRI and Metabolon Announce Strategic Partnership
News Sep 04, 2013
The David H. Murdock Research Institute (DHMRI) and Metabolon, Inc. have announced that they have entered into a strategic agreement to align metabolomics research services.
Metabolon is a pioneering leader in discovery metabolomics and specializes in rapidly assessing metabolism in biological samples to quickly identify prospective biomarkers and to understand metabolic effects of treatments, interventions, nutritionals, etc.
The agreement complements DHMRI’s mass spectrometry and NMR-based metabolomics services through access to Metabolon’s industry-leading high-throughput biomarker discovery and profiling platform which provides an extensive, untargeted, broad metabolite survey of more than 4000 biochemicals.
“This agreement leverages the strengths of our organizations to best serve DHMRI collaborators to understand metabolism and ultimately answer key research questions and deliver healthy food products for consumers. We have worked extensively in food science and nutrition and recognize that our combined resources are indeed complementary. DHMRI is a center of excellence in nutrition research and we are delighted to do our part to meet their growing needs,” says Chris Bernard, Senior Vice President of Sales & Marketing for Metabolon.
DHMRI is an established not-for-profit research institute that provides flexible, client-focused research services to academia, government and industry collaborators.
This agreement, consistent with the DHMRI’s collaborative approach to scientific inquiry, provides partners with additional resources for metabolomics.
Metabolon’s global metabolomic approach can pinpoint active pathways which can be further interrogated by targeted and or customized approaches offered by the DHMRI Metabolomics team.
“We are excited to broaden the breadth of services offered by the DHMRI to our collaborators. The benefits stemming from the collective knowledge of our organizations will be readily realized by researchers, companies and consumers,” said Steve Lommel, Ph.D., Interim President, David H. Murdock Research Institute.
Blood Test To Determine When It Is Safe To Return To Play After A Sports-related ConcussionNews
A high-sensitive blood test can aid concussed hockey players when it might be safe to return to play. In a study published by the journal Neurology, researchers at Sahlgrenska Academy have identified a superior blood-based biomarker for assessing subtle brain injury.READ MORE
Putting Proteins in Their Proper PlaceNews
Everything in the cell has its right place. This includes certain molecules called RNA-binding proteins. When these are misplaced, they can end up causing dangerous clumps that are typical of diseases like ALS. A new study has found a way to send these proteins home.READ MORE
Stable Beta-Amyloid Dimers Identified in Alzheimer’s BrainsNews
A recent study exploited state-of-the-art mass spectrometry to provide the first direct evidence of beta-amyloid dimers in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers. Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.
Comments | 0 ADD COMMENT
6th International Conference on Neurodegenerative Disorders and Stroke
Oct 22 - Oct 23, 2018
16th Annual Conference on Laboratory Medicine and Pathology
Sep 17 - Sep 18, 2018